Información:
Error:
ID
34204
Descripción
RAS Switch in Patients With Metastatic RAS Native Colorectal Tumors Treated With 1st Line FOLFIRI-Cetuximab; ODM derived from: https://clinicaltrials.gov/show/NCT01943786
Link
https://clinicaltrials.gov/show/NCT01943786
Palabras clave
Versiones (1)
- 15/1/19 15/1/19 -
Titular de derechos de autor
see on clinicaltrials.gov
Subido en
15 de enero de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY 4.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Colorectal Cancer Metastatic NCT01943786
Eligibility Colorectal Cancer Metastatic NCT01943786
- StudyEvent: Eligibility
Similar models
Eligibility Colorectal Cancer Metastatic NCT01943786
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
ID.1
Item
diagnosis of stage iv colorectal adenocarcinoma.
boolean
ID.2
Item
patient ≥ 18 years of age.
boolean
ID.3
Item
ecog ps 0-1
boolean
ID.4
Item
life expectancy ≥ 6 months
boolean
ID.5
Item
candidate for first-line systemic chemotherapy according to regular clinical practice.
boolean
ID.6
Item
measurable disease.
boolean
ID.7
Item
wild-type kras
boolean
ID.8
Item
signed informed consent form.
boolean
ID.9
Item
patient who has received prior chemotherapy for metastatic crc, except for adjuvant treatment completed at least six months before entering study.
boolean
ID.10
Item
patient in whom there is a contraindication for the use of any of the drugs used in first-line treatment of colorectal cancer: 5-fluorouracil,, irinotecan or cetuximab
boolean